Boyiadzis M, Wei AH, Paiva B, Freeman SD, et al. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer 2025;131:e35960.
PMID: 40576165